NTRP Market Analysis
Overview
Price chart · mood · technical indicatorsFundamentals
Updated daily after market closeP/E ratio—
EPS (TTM)$-1.820.0% YoY
Profit margin0.0%CONSUMER CYCLICAL
Market cap$29.4MMicro cap
Wall Street coverage
$7.75median target· current $1.73 (+348.0%)2 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Valuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- 5.23
- P/S (TTM)
- 8.14
- EV/EBITDA
- -0.57
Profitability & growth
- ROE (TTM)
- -249.8%
- Operating margin
- -307.2%
- Revenue growth YoY
- 1839.0%
- Dividend yield
- —
- Beta
- 1.57
Last earnings
May 29, 2026 · Estimate $-0.12 · Reported $-0.34
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
News & Sentiment
17 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
About NextTrip Inc
Company profileNeurotrope, Inc., a biopharmaceutical company, is focused on developing a product platform for the treatment of Alzheimer's disease. The company is headquartered in New York, New York.
Classification
- Sector
- Consumer Cyclical
- Industry
- Travel Services
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 3900 PASEO DEL SOL, SANTA FE, NM
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
Market cap$29.4M
Shares outstanding$14.5M
52W high$5.20
52W low$1.80
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent